ANI PHARMACEUTICALS INC (ANIP) Fundamental Analysis & Valuation

NASDAQ:ANIP • US00182C1036

72.49 USD
-3.8 (-4.98%)
At close: Mar 12, 2026
72.49 USD
0 (0%)
After Hours: 3/12/2026, 8:23:10 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ANIP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Overall ANIP gets a fundamental rating of 5 out of 10. We evaluated ANIP against 193 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of ANIP get a neutral evaluation. Nothing too spectacular is happening here. ANIP may be a bit undervalued, certainly considering the very reasonable score on growth These ratings could make ANIP a good candidate for value investing.


Dividend Valuation Growth Profitability Health

5

1. ANIP Profitability Analysis

1.1 Basic Checks

  • ANIP had positive earnings in the past year.
  • In the past year ANIP had a positive cash flow from operations.
  • In the past 5 years ANIP reported 4 times negative net income.
  • In multiple years ANIP reported negative operating cash flow during the last 5 years.
ANIP Yearly Net Income VS EBIT VS OCF VS FCFANIP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

1.2 Ratios

  • ANIP has a better Return On Assets (2.42%) than 82.90% of its industry peers.
  • ANIP's Return On Equity of 6.75% is amongst the best of the industry. ANIP outperforms 84.46% of its industry peers.
  • The Return On Invested Capital of ANIP (5.61%) is better than 83.42% of its industry peers.
Industry RankSector Rank
ROA 2.42%
ROE 6.75%
ROIC 5.61%
ROA(3y)-2.12%
ROA(5y)-3.36%
ROE(3y)-5.31%
ROE(5y)-7.87%
ROIC(3y)N/A
ROIC(5y)N/A
ANIP Yearly ROA, ROE, ROICANIP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 -10

1.3 Margins

  • With an excellent Profit Margin value of 4.13%, ANIP belongs to the best of the industry, outperforming 82.38% of the companies in the same industry.
  • ANIP has a better Operating Margin (9.77%) than 82.90% of its industry peers.
  • In the last couple of years the Operating Margin of ANIP has declined.
  • Looking at the Gross Margin, with a value of 61.14%, ANIP is in the better half of the industry, outperforming 70.98% of the companies in the same industry.
  • ANIP's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 9.77%
PM (TTM) 4.13%
GM 61.14%
OM growth 3YN/A
OM growth 5Y-47.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.51%
GM growth 5Y-3.12%
ANIP Yearly Profit, Operating, Gross MarginsANIP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ANIP Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ANIP is destroying value.
  • There is no outstanding debt for ANIP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANIP Yearly Shares OutstandingANIP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ANIP Yearly Total Debt VS Total AssetsANIP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • ANIP has an Altman-Z score of 2.23. This is not the best score and indicates that ANIP is in the grey zone with still only limited risk for bankruptcy at the moment.
  • ANIP has a better Altman-Z score (2.23) than 64.77% of its industry peers.
  • ANIP has a debt to FCF ratio of 3.98. This is a good value and a sign of high solvency as ANIP would need 3.98 years to pay back of all of its debts.
  • ANIP has a Debt to FCF ratio of 3.98. This is amongst the best in the industry. ANIP outperforms 86.53% of its industry peers.
  • A Debt/Equity ratio of 1.20 is on the high side and indicates that ANIP has dependencies on debt financing.
  • The Debt to Equity ratio of ANIP (1.20) is worse than 72.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.2
Debt/FCF 3.98
Altman-Z 2.23
ROIC/WACC0.61
WACC9.2%
ANIP Yearly LT Debt VS Equity VS FCFANIP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 2.58 indicates that ANIP has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.58, ANIP is in line with its industry, outperforming 47.67% of the companies in the same industry.
  • ANIP has a Quick Ratio of 2.04. This indicates that ANIP is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 2.04, ANIP perfoms like the industry average, outperforming 48.70% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.58
Quick Ratio 2.04
ANIP Yearly Current Assets VS Current LiabilitesANIP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ANIP Growth Analysis

3.1 Past

  • ANIP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.35%, which is quite impressive.
  • The Earnings Per Share has been growing by 17.59% on average over the past years. This is quite good.
EPS 1Y (TTM)51.35%
EPS 3Y77.39%
EPS 5Y17.59%
EPS Q2Q%42.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%29.64%

3.2 Future

  • ANIP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.75% yearly.
  • ANIP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.49% yearly.
EPS Next Y15.55%
EPS Next 2Y17.27%
EPS Next 3Y14.38%
EPS Next 5Y11.75%
Revenue Next Year19.62%
Revenue Next 2Y17.68%
Revenue Next 3Y13.55%
Revenue Next 5Y11.49%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ANIP Yearly Revenue VS EstimatesANIP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
ANIP Yearly EPS VS EstimatesANIP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10

More info and screens

Find the best growth stocksShow best growing peers

8

4. ANIP Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 9.21, the valuation of ANIP can be described as reasonable.
  • Based on the Price/Earnings ratio, ANIP is valued cheaply inside the industry as 91.71% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Earnings ratio of 25.71, ANIP is valued rather cheaply.
  • With a Price/Forward Earnings ratio of 7.97, the valuation of ANIP can be described as very cheap.
  • ANIP's Price/Forward Earnings ratio is rather cheap when compared to the industry. ANIP is cheaper than 91.19% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of ANIP to the average of the S&P500 Index (23.82), we can say ANIP is valued rather cheaply.
Industry RankSector Rank
PE 9.21
Fwd PE 7.97
ANIP Price Earnings VS Forward Price EarningsANIP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ANIP is valued cheaply inside the industry as 86.01% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of ANIP indicates a rather cheap valuation: ANIP is cheaper than 89.64% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 10.44
EV/EBITDA 11.91
ANIP Per share dataANIP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ANIP's earnings are expected to grow with 14.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.59
PEG (5Y)0.52
EPS Next 2Y17.27%
EPS Next 3Y14.38%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ANIP Dividend Analysis

5.1 Amount

  • No dividends for ANIP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ANIP Fundamentals: All Metrics, Ratios and Statistics

ANI PHARMACEUTICALS INC

NASDAQ:ANIP (3/12/2026, 8:23:10 PM)

After market: 72.49 0 (0%)

72.49

-3.8 (-4.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-27
Earnings (Next)05-07
Inst Owners96.24%
Inst Owner Change2.97%
Ins Owners6.27%
Ins Owner Change0.11%
Market Cap1.63B
Revenue(TTM)N/A
Net Income(TTM)34.14M
Analysts84.29
Price Target111.91 (54.38%)
Short Float %17.92%
Short Ratio7.63
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP4.58%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.16%
Min EPS beat(2)14.04%
Max EPS beat(2)24.28%
EPS beat(4)4
Avg EPS beat(4)17.56%
Min EPS beat(4)11.36%
Max EPS beat(4)24.28%
EPS beat(8)8
Avg EPS beat(8)16.28%
EPS beat(12)12
Avg EPS beat(12)41.62%
EPS beat(16)13
Avg EPS beat(16)13.52%
Revenue beat(2)2
Avg Revenue beat(2)7.37%
Min Revenue beat(2)5.83%
Max Revenue beat(2)8.9%
Revenue beat(4)4
Avg Revenue beat(4)7.06%
Min Revenue beat(4)5.83%
Max Revenue beat(4)8.9%
Revenue beat(8)8
Avg Revenue beat(8)5.8%
Revenue beat(12)12
Avg Revenue beat(12)9.19%
Revenue beat(16)15
Avg Revenue beat(16)7.44%
PT rev (1m)0%
PT rev (3m)0.52%
EPS NQ rev (1m)-0.62%
EPS NQ rev (3m)-1.91%
EPS NY rev (1m)-0.17%
EPS NY rev (3m)1.26%
Revenue NQ rev (1m)-0.31%
Revenue NQ rev (3m)0.06%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)0.48%
Valuation
Industry RankSector Rank
PE 9.21
Fwd PE 7.97
P/S 1.97
P/FCF 10.44
P/OCF 9.52
P/B 3.21
P/tB N/A
EV/EBITDA 11.91
EPS(TTM)7.87
EY10.86%
EPS(NY)9.09
Fwd EY12.55%
FCF(TTM)6.95
FCFY9.58%
OCF(TTM)7.61
OCFY10.5%
SpS36.88
BVpS22.56
TBVpS-2.52
PEG (NY)0.59
PEG (5Y)0.52
Graham Number63.21
Profitability
Industry RankSector Rank
ROA 2.42%
ROE 6.75%
ROCE 7.1%
ROIC 5.61%
ROICexc 7.37%
ROICexgc 21.01%
OM 9.77%
PM (TTM) 4.13%
GM 61.14%
FCFM 18.83%
ROA(3y)-2.12%
ROA(5y)-3.36%
ROE(3y)-5.31%
ROE(5y)-7.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-44.22%
ROICexc growth 3YN/A
ROICexc growth 5Y-46.62%
OM growth 3YN/A
OM growth 5Y-47.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.51%
GM growth 5Y-3.12%
F-Score7
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 1.2
Debt/FCF 3.98
Debt/EBITDA 3.51
Cap/Depr 16.39%
Cap/Sales 1.81%
Interest Coverage 2.94
Cash Conversion 99.13%
Profit Quality 456.13%
Current Ratio 2.58
Quick Ratio 2.04
Altman-Z 2.23
F-Score7
WACC9.2%
ROIC/WACC0.61
Cap/Depr(3y)17.9%
Cap/Depr(5y)14.57%
Cap/Sales(3y)2.42%
Cap/Sales(5y)2.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.35%
EPS 3Y77.39%
EPS 5Y17.59%
EPS Q2Q%42.94%
EPS Next Y15.55%
EPS Next 2Y17.27%
EPS Next 3Y14.38%
EPS Next 5Y11.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%29.64%
Revenue Next Year19.62%
Revenue Next 2Y17.68%
Revenue Next 3Y13.55%
Revenue Next 5Y11.49%
EBIT growth 1Y279.28%
EBIT growth 3YN/A
EBIT growth 5Y-34.31%
EBIT Next Year49.94%
EBIT Next 3Y29.56%
EBIT Next 5Y22.28%
FCF growth 1Y159.17%
FCF growth 3Y297.63%
FCF growth 5Y4.15%
OCF growth 1Y144.51%
OCF growth 3Y168.16%
OCF growth 5Y7.01%

ANI PHARMACEUTICALS INC / ANIP FAQ

What is the fundamental rating for ANIP stock?

ChartMill assigns a fundamental rating of 5 / 10 to ANIP.


Can you provide the valuation status for ANI PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 8 / 10 to ANI PHARMACEUTICALS INC (ANIP). This can be considered as Undervalued.


Can you provide the profitability details for ANI PHARMACEUTICALS INC?

ANI PHARMACEUTICALS INC (ANIP) has a profitability rating of 5 / 10.


How financially healthy is ANI PHARMACEUTICALS INC?

The financial health rating of ANI PHARMACEUTICALS INC (ANIP) is 5 / 10.


How sustainable is the dividend of ANI PHARMACEUTICALS INC (ANIP) stock?

The dividend rating of ANI PHARMACEUTICALS INC (ANIP) is 0 / 10 and the dividend payout ratio is 4.58%.